

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM368726

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	NUNC PRO TUNC ASSIGNMENT		
EFFECTIVE DATE:	12/29/2015		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Maxim Pharmaceuticals, Inc.		01/06/2016	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	Immune Pharmaceuticals, Inc.		
Street Address:	430 East 29th Street, Suite 940		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10016		
Entity Type:	CORPORATION: DELAWARE		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Registration Number:	4214414	CEPLENE	
Registration Number:	2967403	CEPLENE	
CORRESPONDENCE DATA			
Fax Number:	9497609502		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	(949) 760-0404		
Email:	efiling@knobbe.com		
Correspondent Name:	Lori L. Yamato		
Address Line 1:	2040 Main Street, 14th Floor		
Address Line 4:	Irvine, CALIFORNIA 92614		
ATTORNEY DOCKET NUMBER:	MAXIM.157T/221T		
NAME OF SUBMITTER:	Charlene A. Azema, Member CA bar		
SIGNATURE:	/charlene a. azema/		
DATE SIGNED:	01/11/2016		
Total Attachments: 2			
source=Confirmation of Trademark Assignment - U.S. Trademarks#page1.tif			
source=Confirmation of Trademark Assignment - U.S. Trademarks#page2.tif			

OP \$65.00 4214414

Confirmation of Trademark Assignment

This Confirmation of Trademark Assignment, effective as of December 29, 2015, is by and between **MAXIM PHARMACEUTICALS, INC.**, a Delaware corporation ("**ASSIGNOR**"), and **IMMUNE PHARMACEUTICALS, INC.**, a Delaware corporation ("**ASSIGNEE**").

ASSIGNOR hereby confirms that, for good and adequate consideration, the receipt and sufficiency of which is hereby acknowledged, as of the Effective Date set forth above, it has assigned and transferred, and hereby assigns and transfers to the extent that it has not already done so, to ASSIGNEE, its successors, legal representatives, and assigns, the entire right, title, and interest throughout the world in, to, and under (i) the trademarks, trademark applications and registrations listed on Schedule 1, attached hereto and hereby incorporated by this reference (collectively, "**Registrations**"); (ii) all other rights appurtenant to the Registrations, including without limitation, the goodwill associated with or symbolized by the marks, all common law rights, trade name rights, causes of action and the right to recover for past infringement ("**Related Rights**"); and (iii) certain tangible assets as indicia of the goodwill in the Registrations and Related Rights.

IN WITNESS WHEREOF, the parties have caused this instrument to be executed, effective as of the day and year first above written.

MAXIM PHARMACEUTICALS, INC.

By: _____

Name: Dr. Daniel Teper

Title: CEO

Date: 1/6/2016

IMMUNE PHARMACEUTICALS, INC.

By: _____

Name: Dr. Daniel Teper

Title: CEO

Date: 1/6/2016

Schedule 1

US Matters

Trademarks Applications

Application No.	Patent No.
85/307577	
86/437617	
75/045348	2095894
75/146908	
75/146909	2182777
76/138210	
76/138211	3252103
76/138212	2967403
85/009435	
85/021009	4214414

